C-Reactive protein and interleukin-6 serum levels increase as chagas disease progresses towards cardiac failure;Las concentraciones séricas de interleucina-6 proteína C reactiva se incrementan a medida que la enfermedad de chagas evoluciona hacia el deteriora de la función cardíaca

Revista Espanola de Cardiologia

Volumn 59, Issue 1, 2006, Pages 50-56

  López, Lynkis ^a   Arai, Kaduo ^a   Giménez, Esther ^a   Jiménez, Mariela ^a   Pascuzo, Carmine ^a   Rodríguez Bonfante, Claudina ^a   Bonfante Cabarcas, Rafael ^a  

^a UNIVERSIDAD CENTROCCIDENTAL LISANDRO ALVARADO   (Venezuela)

Author keywords

C reactive protein; Chagasic cardiomyopathy; Interleukin 6

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6;

ADULT; ARTICLE; CHAGAS DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE MASS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PROGNOSIS; PROTEIN BLOOD LEVEL;

EID: 33344465606     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13083649     Document Type: Article

References (25)

1. Rassi A, Tranchesi J, Tranchesi B. Doencças de Chagas. En: Veronesi A, editor. Doenças Infecciosas Parasitarias. Río de Janeiro: Guanabara Koogan, 1991. p. 674-705.
2. Moncayo A. Chagas' disease: current epidemiological trends after the interruption of vectorial and transfusional transmission in the southern cone countries. Mem Inst Oswaldo Cruz. 2003; 98:577-91.
3. Marin Neto JA, Simoes MV, Sarabanda AV. Chagas' heart disease. Arq Bras Cardiol. 1999;72:247-80.
4. OPS/OMS Venezuela. Análisis preliminar de la situación de salud de Venezuela. OPS/OMS Representación para Venezuela, Aruba y Antillas Holandesa, 2002 [17 screns]. Disponible en: http://www.ops-oms.org.ve/site/venezuela/ven-sit-salud-nuevo.htm
5. Ministerio de Sanidad y Asistencia Social, República de Venezuela. Caracas: Anuario Epidemiológico y Estadística Vital; 1996. p. 294-6.
6. Cardoni RL. Inflammatory response to acute Trypanosoma cruzi infection. Medicina (Buenos Aires). 1997;57:227-34.
7. Briceno L, Mosca W. Defective production of interleukin 2 in patients with Chagas' disease. Purified IL-2 augments in vitro response in patients with chagasic cardiomyopathy. Mem Inst Oswaldo Cruz. 1996;91:601-7.
8. Laucella SA, Rottenberg ME, de Titto EH. Role of cytokines in resistance and pathology in Trypanosoma cruzi infection. Rev Argent Microbiol. 1996;28:99-109.
9. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003; 111:1805-12.
10. Medrano NM, Luz MR, Cabello PH, Tapia GT, Van Leuven F, Araujo-Jorge TC. Acute Chagas' disease: plasma levels of alpha-2-macroglobulin and C-reactive protein in children under 13 years in a high endemic area of Bolivia. J Trop Pediatr. 1996;42:68-74.
11. Medrano-Mercado N, Luz MR, Torrico F, Tapia G, Van Leuven F, Araujo-Jorge TC. Acute-phase proteins and serologic profiles of chagasic children from an endemic area in Bolivia. Am J Trop Med Hyg. 1996;54:154-61.
12. Cetron MS, Basilio FP, Moraes AP, Sousa AQ, Paes JN, Kahn SJ, et al. Humoral and cellular immune response of adults from northeastern Brazil with chronic Trypanosoma cruzi infection: depressed cellular immune response to T. cruzi antigen among Chagas' disease patients with symptomatic versus indeterminate infection. Am J Trop Med Hyg. 1993;49:370-82.
13. Kanda T, Takahashi T. Interleukin-6 and cardiovascular diseases. Jpn Heart J. 2004;45:183-93.
14. Gao W, Pereira MA. Interleukin-6 is required for parasite specific response and host resistance to Trypanosoma cruzi. Int J Parasitol. 2002;32:167-70.
15. Truyens C, Angelo-Barrios A, Torrico F, Van Damme J, Heremans H, Carlier Y. Interleukin-6 (IL-6) production in mice infected with Trypanosoma cruzi: effect of its paradoxical increase by anti-IL-6 monoclonal antibody treatment on infection and acute-phase and humoral immune responses. Infect Immun. 1994;62: 692-6.
16. Saavedra E, Herrera M, Gao W, Uemura H, Pereira MA. The Trypanosoma cruzi trans-sialidase, through its COOH-terminal tandem repeat, upregulates interleukin 6 secretion in normal human intestinal microvascular endothelial cells and peripheral blood mononuclear cells. J Exp Med. 1999; 190:1825-36.
17. Añez N, González N, Crisante G, Rojas A, Premoli G, Ramírez JL, et al. Curso Taller: Pruebas confirmatorias en el diagnóstico de la enfermedad de Chagas. XVIII Jornadas José Witremundo Torrealba. San Carlos, Venezuela, 1999.
18. Carrasco HA, Parada H, Guerrero L, Duque M, Durán D, Molina C. Prognostic implications of clinical, electrocardiographic and hemodynamic findings in chronic Chagas' disease. Int J Cardiol. 1994;43:27-38.
19. Basquiera AL, Sembaj A, Aguerri AM, Omelianiuk M, Guzmán S, Moreno Barral J, et al. Risk progression to chronic Chagas cardiomyopathy: influence of male sex and of parasitaemia detected by polymerase chain reaction. Heart. 2003;89:1186-90.
20. Acquatella H, Catalioti F, Gómez-Mancebo JR, Davalos V, Villalobos L. Long-term control of Chagas disease in Venezuela: effects on serologic findings, electrocardiographic abnormalities and clinical outcome. Circulation. 1987;76:556-62.
21. Milei J, Stornino R, Jorg M, Chiale P, Schetjman D, Sterin-Borda E, et al. Patogenia. En: Storino R, Milei J, editores. Enfermedad de Chagas. Buenos Aires: Editorial Doyma Argentina S.A.; 1994. p. 103-28.
22. Cunha-Neto E, Kalil J. Autoimmunity in Chagas' heart disease. Sao Paulo Med J. 1995;113:757-66.
23. Rossi MA. Microvascular changes as a cause of chronic cardiomyopathy in Chagas' disease. Am Heart J. 1990;120:233-6.
24. Sato Y, Takatsu Y, Kataoka K, Yamada T, Taniguchi R, Sasayama S, et al. Serial circulating concentrations of C-reactive protein, interleukin (IL)-4, and IL-6 in patients with acute left heart decompensation. Clin Cardiol. 1999;22:811-3.
25. Petretta M, Condorelli GL, Spinelli L, Scopacasa F, De Caterina M, Leosco D, et al. Circulating levels of cytokines and their site of production in patients with mild to severe chronic heart failure. Am Heart J. 2000;140:E28.